CDER Dispute Resolution Process Gained Prominence In 2007
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's formal dispute resolution process had a higher profile in 2007 than previous years, suggesting that the rising number of multiple action letters and increasingly vocal criticism of FDA intransigence likely have contributed to the trend of more - or more public - formal appeals